Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer

Glycolysis is elevated in many cancers. In this study, the authors show that lactoylglutathione, a by-product of methylglyoxal produced from increased glycolysis, is elevated in lung cancer in mouse models and humans, arguing reactive metabolite production can be a liability for cancers.

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Alba Luengo, Keene L. Abbott, Shawn M. Davidson, Aaron M. Hosios, Brandon Faubert, Sze Ham Chan, Elizaveta Freinkman, Lauren G. Zacharias, Thomas P. Mathews, Clary B. Clish, Ralph J. DeBerardinis, Caroline A. Lewis, Matthew G. Vander Heiden
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2019
Sujets:	Science Q
Accès en ligne:	https://doaj.org/article/ffedc81cd29a41c396c00462dba0a351
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:ffedc81cd29a41c396c00462dba0a351
record_format	dspace
spelling	oai:doaj.org-article:ffedc81cd29a41c396c00462dba0a3512021-12-02T15:35:29ZReactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer10.1038/s41467-019-13419-42041-1723https://doaj.org/article/ffedc81cd29a41c396c00462dba0a3512019-12-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-13419-4https://doaj.org/toc/2041-1723Glycolysis is elevated in many cancers. In this study, the authors show that lactoylglutathione, a by-product of methylglyoxal produced from increased glycolysis, is elevated in lung cancer in mouse models and humans, arguing reactive metabolite production can be a liability for cancers.Alba LuengoKeene L. AbbottShawn M. DavidsonAaron M. HosiosBrandon FaubertSze Ham ChanElizaveta FreinkmanLauren G. ZachariasThomas P. MathewsClary B. ClishRalph J. DeBerardinisCaroline A. LewisMatthew G. Vander HeidenNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Alba Luengo Keene L. Abbott Shawn M. Davidson Aaron M. Hosios Brandon Faubert Sze Ham Chan Elizaveta Freinkman Lauren G. Zacharias Thomas P. Mathews Clary B. Clish Ralph J. DeBerardinis Caroline A. Lewis Matthew G. Vander Heiden Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
description	Glycolysis is elevated in many cancers. In this study, the authors show that lactoylglutathione, a by-product of methylglyoxal produced from increased glycolysis, is elevated in lung cancer in mouse models and humans, arguing reactive metabolite production can be a liability for cancers.
format	article
author	Alba Luengo Keene L. Abbott Shawn M. Davidson Aaron M. Hosios Brandon Faubert Sze Ham Chan Elizaveta Freinkman Lauren G. Zacharias Thomas P. Mathews Clary B. Clish Ralph J. DeBerardinis Caroline A. Lewis Matthew G. Vander Heiden
author_facet	Alba Luengo Keene L. Abbott Shawn M. Davidson Aaron M. Hosios Brandon Faubert Sze Ham Chan Elizaveta Freinkman Lauren G. Zacharias Thomas P. Mathews Clary B. Clish Ralph J. DeBerardinis Caroline A. Lewis Matthew G. Vander Heiden
author_sort	Alba Luengo
title	Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
title_short	Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
title_full	Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
title_fullStr	Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
title_full_unstemmed	Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
title_sort	reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/ffedc81cd29a41c396c00462dba0a351
work_keys_str_mv	AT albaluengo reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer AT keenelabbott reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer AT shawnmdavidson reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer AT aaronmhosios reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer AT brandonfaubert reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer AT szehamchan reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer AT elizavetafreinkman reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer AT laurengzacharias reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer AT thomaspmathews reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer AT clarybclish reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer AT ralphjdeberardinis reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer AT carolinealewis reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer AT matthewgvanderheiden reactivemetaboliteproductionisatargetableliabilityofglycolyticmetabolisminlungcancer
_version_	1718386574269349888

Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer

Documents similaires